We are your scientific partner of choice.
| Collaborator | Drug Candidate | Disease |
|---|---|---|
 |
Emavusertib (Oral Small Molecule IRAK4 Inhibitor) | Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes |
 |
Fimepinostat | Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma |
 |
Fimepinostat | Hematologic and solid malignancies |
 |
Fimepinostat | Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG) |
Investigators may request Curis to provide its compounds for clinical and non-clinical study purposes. Any information that you submit below is subject to our Privacy Policy.
Investigator-Sponsored Trial (IST) or Investigator-Initiated Trial (IIT)
Similar to clinical studies, IST or IIT studies provide qualifying patients with access to investigational drugs. Data is collected to better understand safety and efficacy where the sponsor-investigator assumes responsibility for all aspects of the research.
For IST or IIT requests by physicians click here
Material Transfer Agreement (MTA)
A request by an external entity (e.g. academic or research institution) to conduct research and/or collaborate on a Curis compound. Only compound material will be provided for this agreement.
For an MTA Request click here
Sponsor Research Agreement (SRA)
A request by an external entity (e.g. academic or research institution) to conduct research and/or collaborate on a Curis compound. This request includes funding to support the research plan.
For an SRA request click here